Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus–positive recipients of living donor liver transplantation
Open Access
- 21 May 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 19 (8) , 896-906
Abstract
The purpose of this prospective, randomized, multicenter trial was to evaluate the effects of a steroid-avoiding immunosuppression protocol on hepatitis C virus (HCV)–positive recipients of living donor liver transplantation (LDLT). Seventy-five HCV-positive LDLT recipients were included in this study, and they were randomized to receive tacrolimus (TAC) plus a corticosteroid (ST; n = 35) or TAC plus mycophenolate mofetil (MMF; n = 40). Biopsy-proven acute rejection (BPAR) was treated with steroid pulse therapy in both groups. Protocol biopsy was performed 3, 6, and 12 months after LDLT and annually thereafter. Histological recurrence of HCV (fibrosis stage ≥ F1 according to the METAVIR score), BPAR resistant to 2 sets of steroid pulse therapy, hepatocellular carcinoma (HCC) recurrence, retransplantation, and patient death were defined as events, and the primary endpoint was event-free survival. The median follow-up was 55 months. The event-free survival rates at 1, 3, and 5 years were 38.2%, 11.8%, and 5.9%, respectively, for the ST group and 25.0%, 17.5%, and 14.6%, respectively, for the MMF group (P = 0.45). The overall 5-year patient survival rates were similar for the ST group (82.7%) and the MMF group (81.0%, P = 0.28). Steroid-resistant BPAR occurred in only 1 patient from the MMF group. HCC recurrence occurred for 1 patient from the ST group and 2 patients from the MMF group. HCV recurrence rates with a fibrosis stage ≥ F1 1 and 3 years after LDLT were 59.4% and 85.9%, respectively, for the ST group and 74.2% and 81.9%, respectively, for the MMF group (P = 0.57). In conclusion, our steroid-avoidance regimen had no apparent impact on LDLT outcomes for HCV-positive recipients.Keywords
This publication has 35 references indexed in Scilit:
- Cyclosporine versus Tacrolimus Treated Liver Transplant Recipients with Chronic Hepatitis C: Outcomes Analysis of the UNOS/OPTN DatabaseAmerican Journal of Transplantation, 2011
- A Practical Guide to the Management of HCV Infection Following Liver TransplantationAmerican Journal of Transplantation, 2009
- Randomized Trial of Steroid-Free Induction Versus Corticosteroid Maintenance Among Orthotopic Liver Transplant Recipients With Hepatitis C Virus: Impact on Hepatic Fibrosis Progression at One YearTransplantation, 2007
- A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis CTransplant International, 2005
- Double-Blind Comparison of Hepatitis C Histological Recurrence Rate in HCV+ Liver Transplant Recipients Given Basiliximab+Steroids or Basiliximab+Placebo, in addition to Cyclosporine and AzathioprineTransplantation, 2004
- FACTORS DIFFERENTIALLY CORRELATED WITH THE OUTCOME OF LIVER TRANSPLANTATION IN HCV+ AND HCV- RECIPIENTSTransplantation, 2004
- The natural history and outcome of liver transplantation in hepatitis C virus-infected recipientsLiver Transplantation, 2003
- Report of the First International Liver Transplantation Society Expert Panel Consensus Conference on Liver Transplantation and Hepatitis CLiver Transplantation, 2003
- Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipientsHepatology, 2002
- High Incidence of Allograft Cirrhosis in Hepatitis C Virus Genotype 1B Infection Following Transplantation: Relationship With Rejection EpisodesHepatology, 1999